Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
RIGL - Rigel Pharmaceuticals
$3.76
0.00(0.00%)5:00:00 AM 1/15/2021
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news